# Santarus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/santarus

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.santarus.com
- Total disclosed funding: $89M
- Latest round: Series D (May 22, 2003)
- Investors on record: 11

## About

Santarus, Inc. is a biopharmaceutical company specializing in developing and commercializing innovative therapies for gastrointestinal diseases. It aims to enhance patient care with its focused product pipeline.Founded in 1996, Santarus, Inc. is located in San Diego, US. The company focuses on developing therapeutics for gastrointestinal conditions. It raised USD 54 mn in an Initial Public Offering on the Nasdaq stock market in December 2007, marking a significant milestone in its funding history. The company saw a decrease in ownership stakes from its investors, Advent Venture Partners, Domain Associates, and J.P. Morgan Partners, who previously held substantial shares. CEO Gerry Proehl has been instrumental in guiding the company through its strategic phases.Santarus, Inc. specializes in biopharmaceutical products targeted at gastrointestinal diseases. The company’s primary offerings include prescription therapies aimed at reducing symptoms of various gastrointestinal conditions, with focus on enhancing the quality of life for patients suffering from these ailments. Santarus targets a diverse clientele within the healthcare sector, ranging from hospitals to specialized clinics.In 2012, Santarus, Inc. reported revenue of USD 217.96 mn and an EBITDA of USD 26.30 mn for the same year, reflecting its operational performance during that period. Revenue generation comes from a mix of product sales and partnerships with healthcare providers.Post-IPO, Santarus, Inc. is focused on expanding its product pipeline to include new therapies aimed at unmet medical needs in gastrointestinal health. The company is exploring opportunities for market expansion into regions such as Europe and Asia-Pacific by 2015, leveraging its recent funding to support research and development initiatives. The funds raised during the IPO will be utilized to enhance its product development capabilities and to navigate regulatory pathways for upcoming product launches, further solidifying its market presence.

## Funding rounds

- Series D, May 22, 2003, $51M — Domain Associates, New England Partners, CDIB Capital Group, EQT Life Sciences, Hamilton BioVentures, St. Paul Venture Capital, SR One, Windamere Venture Partners, JP Morgan Asset Management, Fog City Capital, Advent Life Sciences
- Series C, Mar 7, 2001, $33M — Domain Associates, St. Paul Venture Capital, Windamere Venture Partners, JP Morgan Asset Management, Fog City Capital, Advent Life Sciences
- Series B, Aug 17, 1999, $4.8M — St. Paul Venture Capital, Windamere Venture Partners, Fog City Capital

## Investors

- St. Paul Venture Capital (https://capitalatlas.ai/funds/st-paul-venture-capital) — Series B, Series C, Series D
- Windamere Venture Partners (https://capitalatlas.ai/funds/windamere-venture-partners) — Series B, Series C, Series D
- Fog City Capital (https://capitalatlas.ai/funds/fog-city-capital) — Series B, Series C, Series D
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series C, Series D
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series C, Series D
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series C, Series D
- New England Partners (https://capitalatlas.ai/funds/new-england-partners) — Series D
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series D
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series D
- Hamilton BioVentures (https://capitalatlas.ai/funds/hamilton-bioventures) — Series D
- SR One (https://capitalatlas.ai/funds/sr-one) — Series D